ABSTRACT
Objectives: The main purpose of this study was to determine the frequency of COVID-19 vaccine side effects in patients with rheumatic diseases and to examine any potential associations with medications, disease type, or comorbidities. Methods: A multicentre cross-sectional study from rheumatology units in different hospitals in Iraq was carried out between 8th of August 2021 and 4th of August 2022. Patients were eligible for inclusion if they have a rheumatic disease and have taken one or more doses of any COVID-19 vaccine. Results: A total of 661 (57.8% female, mean age 46.51± 12.97 years) patients with rheumatic illnesses who received the "COVID-19" vaccination were included in this study. Rheumatoid arthritis was the most frequent diagnostic group. The Pfizer vaccine was given to the majority of patients (74.6%), followed by Sinopharm (16.2%), and AstraZeneca (9.2%). Side effects were detected in 661(100%) and 528 (100%) patients following the first and second vaccination doses, respectively; among which the most frequent were injection site pain in 57.8% following the first dose and 47.6% after the second dose, followed by fatigue and fever. According to multivariate logistic regression models, age (B=-0.204, p = 0.000), had a significantly inverse correlation coefficient with the experience of greater side effects. Rheumatic disease flares reported in 9.9%, 10.3%, and 8.2% of patients who received the Pfizer, Sinopharm, and AstraZeneca vaccines, respectively. Conclusion: The "COVID-19" vaccination has a reassuring safety profile with no greater risk of adverse events in any specific illness or pharmacological therapy.
ABSTRACT
By reporting this case, we hope to encourage medical professionals to concentrate on diagnosing old patients with unusual presentation of rheumatoid arthritis.
ABSTRACT
Revolution in healthcare can be experienced with the advancement of smart sensorial things, Artificial Intelligence (AI), Machine Learning (ML), Deep Learning (DL), Internet of Medical Things (IoMT), and edge analytics with the integration of cloud computing. Connected healthcare is receiving extraordinary contemplation from the industry, government, and the healthcare communities. In this study, several studies published in the last 6 years, from 2016 to 2021, have been selected. The selection process is represented through the Prisma flow chart. It has been identified that these increasing challenges of healthcare can be overcome by the implication of AI, ML, DL, Edge AI, IoMT, 6G, and cloud computing. Still, limited areas have implemented these latest advancements and also experienced improvements in the outcomes. These implications have shown successful results not only in resolving the issues from the perspective of the patient but also from the perspective of healthcare professionals. It has been recommended that the different models that have been proposed in several studies must be validated further and implemented in different domains, to validate the effectiveness of these models and to ensure that these models can be implemented in several regions effectively.
